Thank you, Mr. Chair.
I will take advantage of your presence, Dr. Quach-Thanh, to ask you some questions.
First, I would like to thank you for being with us again. You have come to see us a few times. I hope that we will be able to get a copy of your speech as well as all of the speeches that were given today. As yours was very technical, I'd like to try to put it all in a little simpler terms. People have concerns. Mr. Powlowski spoke earlier about the issue of a single dose and the interval between two doses. People are concerned about whether they should get booster shots.
The data presented yesterday by the Institut national de santé publique du Québec, or INSPQ, was quite intriguing. It was good news. Basically, the INSPQ told us that the first dose of the vaccine is 85% effective and that the second dose would only increase effectiveness by 10%. In addition, the second dose could increase the duration of protection, but it's unclear how long that duration would be. However, it is also possible that a single dose could lead to revaccination.
Given the fact that as many people as possible would need to be vaccinated to achieve herd immunity, what do you think of this news? Do you feel the second dose is necessary? Isn't it just a prerogative of a company that wants to promote its brand and make doubly sure that it's going to work? This information is a total game-changer.